1940-1970年代，中国表观遗传学处于探索奠基阶段。1942年，英国生物学家Conrad Waddington首次提 出"表观遗传学"概念，但中国受苏联李森科主义影响，遗传学发展受阻。1950年代，摩尔根学派被压 制，表观遗传学研究停滞。1952年高校院系调整削弱了清华大学、浙江大学等高校的遗传学专业。1956 年"青岛会议"后遗传学短暂发展，但"文化大革命"期间研究再次受冲击。1978年中国遗传学会成立，遗 传学研究恢复发展，为表观遗传学奠定基础。 1980-1990年代，中国表观遗传学进入初步发展阶段。改革开放后，中国引进国际先进遗传学理论，表 观遗传学逐渐被引入。1980年代，DNA甲基化、组蛋白修饰等机制开始被研究。1990年代，中国科学 家参与国际研究，如1996年C. David Allis发现组蛋白乙酰转移酶。1990年代，中国启动"863计划""973 计划"等，支持遗传学与表观遗传学研究。 内容概况：近年来，中国表观遗传学行业取得了显著进展，逐渐成为生命科学领域的研究热点。2024 年，中国表观遗传学行业市场规模约为43.96亿元，同比增长62.27%。这不仅反映了技术的不断进步， 也体 ...

Core Viewpoint - Zhejiang University has announced multiple government procurement intentions for laboratory instruments, with a total budget of 108 million yuan, covering 22 items including advanced analytical and measurement equipment [2][3]. Procurement Overview - The procurement includes high-performance instruments such as the ZJE Cell Flow Cytometer, fluid PVT relationship measurement teaching system, and signal and spectrum analyzers, with expected procurement dates set for July to October 2025 [3][4][6]. Specific Instruments - **ZJE Cell Flow Cytometer**: A multi-parameter cell analysis device used in life sciences, clinical diagnostics, and drug development [4]. - **Flow Cytometric Sorter**: An advanced device for quantitative analysis and precise separation of target cell populations, crucial for fields like cell biology and oncology [5]. - **Signal and Spectrum Analyzer**: A core electronic measurement device for capturing and analyzing electrical signals, widely used in communications and aerospace [6]. Detailed Procurement List - The procurement list includes various instruments with specific budget allocations, such as: - Sample pretreatment system and high-brightness UV light source: 2.64 million yuan [8]. - GPU servers for AI integration: 21 million yuan for 15 units [9]. - 12-inch silicon germanium epitaxy system: 9.9 million yuan [9]. - Flow cytometric sorter for medical applications: 3.5 million yuan [11]. - Dilution refrigeration ultra-low temperature measurement system: 1.99 million yuan [11]. Budget and Timeline - The total budget for the procurement is 108 million yuan, with procurement expected to occur between July and October 2025 [2][3].

Core Insights - The life sciences instrument sector is experiencing significant capital inflow and technological innovation in 2025, with a notable trend towards domestic substitution [1][2] - The financing activity in the first half of 2025 has surpassed that of the same period in 2024, with a total of approximately 1.5 billion yuan raised across 13 financing events [2] Financing Overview - In the first half of 2025, 13 financing events were completed, totaling around 1.5 billion yuan, with a balanced distribution across various financing rounds: 4 in A round, 4 in B round, 3 in C round, and 2 in angel round [2] - Key financing events include: - Kunpeng Gene: over 100 million yuan in B round [2] - Yinsais: several hundred million yuan in C round [2] - Zhenmai Bio: 280 million yuan in C+ round, the highest amount in the first half [3][2] Sector Analysis - Sequencing and synthetic biology are leading the investment landscape, with sequencing-related companies accounting for over 30% of the financing events [3] - The market for sequencing instruments is expected to maintain a compound annual growth rate of over 20% due to increasing demand for precision medicine and single-cell sequencing [3] Synthetic Biology Financing - Synthetic biology has emerged as a hot investment area since 2024, continuing into 2025, with significant financing amounts [4] - Companies like Yinsais and Lingzhi Technology are focusing on nucleic acid synthesis and DNA synthesis, respectively, aligning with global trends in mRNA technology [4] AI and Advanced Instrumentation - Companies are integrating AI with high-end instrumentation, exemplified by Tianlu Technology's intelligent experimental design tools and Chaowei Jing's multi-photon microscope [5] - This trend indicates a shift towards interdisciplinary innovation, enhancing the competitiveness of domestic instruments [5] Domestic Instrumentation Landscape - Lid Health's substantial angel round financing has drawn attention, positioning the company as a comprehensive supplier of high-end life science instruments [6] - The company aims to consolidate the market by acquiring smaller players, drawing parallels with international leaders like Thermo Fisher [6] Policy and Market Dynamics - The rapid development of domestic life science instruments is driven by supportive policies and growing market demand, particularly in biomedicine and CGT sectors [7] - Despite active financing, domestic manufacturers face challenges such as reliance on imported core components and the need for brand recognition [7] Future Outlook - The life sciences instrument sector is expected to see a shift from broad investment strategies to a more focused approach, favoring companies with high technological barriers and significant domestic substitution potential [8] - The industry is anticipated to produce several "hidden champions" in niche areas within the next 3-5 years, moving towards the high end of the global value chain [8]

Core Viewpoint - Beijing University of Chinese Medicine has announced multiple government procurement intentions for laboratory equipment, with a total budget of 116 million yuan [2][3]. Procurement Projects Summary - **Project for the Construction of Experimental and Practical Platforms for the School of Traditional Chinese Medicine**: Aimed at enhancing the practical teaching base, the project includes the purchase of 22 pieces of equipment and 10 chiral chromatography columns, with a budget of 1.5 million yuan, scheduled for April 2025 [4]. - **Project for the Improvement of Teaching Conditions for the School of Traditional Chinese Medicine**: This project addresses urgent needs for teaching operations and includes 32 items for digital imaging of pathological specimens, among other equipment, with a budget of 1.47 million yuan, also set for April 2025 [4]. - **High-Fidelity Human Engineering Platform Procurement**: This project involves purchasing small equipment to support a national-level platform, with a budget of 4.95 million yuan, planned for April 2025 [4]. - **Equipment Procurement for the Innovation Service Platform for Traditional Chinese Medicine Constitution and Chronic Disease Prevention**: This project focuses on essential equipment for life sciences, including PCR machines and various types of refrigerators, with a budget of 4.95 million yuan, scheduled for April 2025 [5]. - **Basic and Pharmaceutical Biological Evaluation Teaching Platform Construction Project**: This project aims to upgrade the teaching platform and includes 83 pieces of equipment, with a budget of 4.95 million yuan, planned for April 2025 [5]. - **Research and Pilot Testing Platform for Innovative Chinese Medicine**: This project will acquire a range of research equipment for the development of innovative Chinese medicine, including high-performance liquid chromatography systems and various analytical instruments, with a budget of 4.95 million yuan, scheduled for April 2025 [5].

Core Insights - The strategic cooperation between Kangsheng Zhenyuan and Zhenmai Bio aims to develop NGS testing products and solutions tailored to clinical needs in the fields of oncology, genetics, and pharmacogenomics [1][2] - This partnership signifies a significant step forward for China's high-throughput sequencing technology and its application in precision medicine [2] Company Overview - Kangsheng Global, a leader in precision medicine in China, has extensive clinical testing experience and a diversified testing platform [1] - Kangsheng Zhenyuan has made breakthroughs in NGS applications, expanding its product matrix to meet the growing demand for specialized testing in oncology and genetic diseases [1] - Zhenmai Bio focuses on the research and production of gene sequencers and life science instruments, with its high-throughput sequencer achieving international leading levels in throughput, accuracy, and cost [1] Strategic Collaboration - The collaboration will leverage the strengths of both companies in R&D, application, and market promotion of high-throughput sequencing technology [1] - The goal is to create an ecological closed loop in the high-throughput sequencing field, enhancing the innovation and application of domestic sequencing technology [1]